|
1
|
Valle JW, Kelley RK, Nervi B, Oh DY and
Zhu AX: Biliary tract cancer. Lancet. 397:428–444. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kang MJ, Jung KW, Bang SH, Choi SH, Park
EH, Yun EH, Kim HJ, Kong HJ, Im JS and Seo HG: Community of
population-based regional cancer registries*. Cancer statistics in
Korea: Incidence, mortality, survival, and prevalence in 2020.
Cancer Res Treat. 55:385–399. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lee J, Park SH, Chang HM, Kim JS, Choi HJ,
Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, et al: Gemcitabine and
oxaliplatin with or without erlotinib in advanced biliary-tract
cancer: A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 13:181–188. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG
and Lee JS: Cancer statistics in Korea: Incidence, mortality,
survival and prevalence in 2010. Cancer Res Treat. 45:1–14.
2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Banales JM, Marin JJG, Lamarca A,
Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen
JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in
mechanisms and management. Nat Rev Gastroenterol Hepatol.
17:557–588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shi Y, Wang Y, Zhang W, Niu K, Mao X, Feng
K and Zhang Y: N6-methyladenosine with immune infiltration and
PD-L1 in hepatocellular carcinoma: novel perspective to
personalized diagnosis and treatment. Front Endocrinol (Lausanne).
14(1153802)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu
YD and Guo RP: Relationship between PD-L1 expression, CD8+ T-cell
infiltration and prognosis in intrahepatic cholangiocarcinoma
patients. Cancer Cell Int. 21(371)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Xie Q, Wang L and Zheng S: Prognostic and
clinicopathological significance of PD-L1 in patients with
cholangiocarcinoma: A meta-analysis. Dis Markers.
2020(1817931)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee J and Kim DU: Recent Update of
Targeted Therapy in Cholangiocarcinoma. Korean J Pancreas Biliary
Tract. 28:59–66. 2023.(In Korean).
|
|
10
|
Dey S, Chatterjee S, Ghosh S and Sikdar N:
The geographical, ethnic variations and risk factors of gallbladder
carcinoma: A worldwide view. J Investig Genomics. 3:49–54.
2016.
|
|
11
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Guion-Dusserre JF, Lorgis V, Vincent J,
Bengrine L and Ghiringhelli F: FOLFIRI plus bevacizumab as a
second-line therapy for metastatic intrahepatic cholangiocarcinoma.
World J Gastroenterol. 21(2096)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Oh DY, Ruth He A, Qin S, Chen LT, Okusaka
T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, et al:
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract
cancer. NEJM Evid. 1(EVIDoa2200015)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse
J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab
in combination with gemcitabine and cisplatin compared with
gemcitabine and cisplatin alone for patients with advanced biliary
tract cancer (KEYNOTE-966): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 401:1853–1865.
2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sanz-Altamira PM, Ferrante K, Jenkins RL,
Lewis WD, Huberman MS and Stuart KE: A phase II trial of
5-fluorouracil, leucovorin, and carboplatin in patients with
unresectable biliary tree carcinoma. Cancer. 82:2321–2325.
1998.PubMed/NCBI
|
|
16
|
Lamarca A, Palmer DH, Wasan HS, Ross PJ,
Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, et al:
Second-line FOLFOX chemotherapy versus active symptom control for
advanced biliary tract cancer (ABC-06): A phase 3, open-label,
randomised, controlled trial. Lancet Oncol. 22:690–701.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
O'Rourke CJ, Munoz-Garrido P and Andersen
JB: Molecular targets in cholangiocarcinoma. Hepatology. 73 (Suppl
1):S62–S74. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Goyal L, Saha SK, Liu LY, Siravegna G,
Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V,
Kambadakone A, et al: Polyclonal secondary FGFR2 mutations drive
acquired resistance to FGFR inhibition in patients with FGFR2
fusion-positive cholangiocarcinoma. Cancer Discov. 7:252–263.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Javle M, Churi C, Kang HC, Shroff R, Janku
F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, et al:
HER2/neu-directed therapy for biliary tract cancer. J Hematol
Oncol. 8(58)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Riener MO, Bawohl M, Clavien PA and Jochum
W: Rare PIK3CA hotspot mutations in carcinomas of the biliary
tract. Genes Chromosomes Cancer. 47:363–367. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Moeini A, Sia D, Bardeesy N, Mazzaferro V
and Llovet JM: Molecular pathogenesis and targeted therapies for
intrahepatic cholangiocarcinoma. Clin Cancer Res. 22:291–300.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Abou-Alfa GK, Sahai V, Hollebecque A,
Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson
D, Murphy AG, et al: Pemigatinib for previously treated, locally
advanced or metastatic cholangiocarcinoma: A multicentre,
open-label, phase 2 study. Lancet Oncol. 21:671–684.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Makawita S, K Abou-Alfa G, Roychowdhury S,
Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla
T, et al: Infigratinib in patients with advanced cholangiocarcinoma
with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future
Oncol. 16:2375–2384. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rizzo A, Ricci AD and Brandi G:
Futibatinib, an investigational agent for the treatment of
intrahepatic cholangiocarcinoma: Evidence to date and future
perspectives. Expert Opin Investig Drugs. 30:317–324.
2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Abou-Alfa GK, Macarulla T, Javle MM,
Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ,
Bridgewater J, et al: Ivosidenib in IDH1-mutant,
chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A
multicentre, randomised, double-blind, placebo-controlled, phase 3
study. Lancet Oncol. 21:796–807. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cho SM, Esmail A, Raza A, Dacha S and
Abdelrahim M: Timeline of FDA-approved targeted therapy for
cholangiocarcinoma. Cancers (Basel). 14(2641)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Roa I, de Toro G, Schalper K, de
Aretxabala X, Churi C and Javle M: Overexpression of the HER2/neu
gene: A new therapeutic possibility for patients with advanced
gallbladder cancer. Gastrointest Cancer Res. 7:42–48.
2014.PubMed/NCBI
|
|
28
|
Yarlagadda B, Kamatham V, Ritter A,
Shahjehan F and Kasi PM: Trastuzumab and pertuzumab in circulating
tumor DNA ERBB2-amplified HER2-positive refractory
cholangiocarcinoma. NPJ Precis Oncol. 3(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS,
Jang JS, Kim MH, Park S, Kang B, Hong M, et al: Trastuzumab plus
FOLFOX for HER2-positive biliary tract cancer refractory to
gemcitabine and cisplatin: A multi-institutional phase 2 trial of
the Korean cancer study group (KCSG-HB19-14). Lancet Gastroenterol
Hepatol. 8:56–65. 2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW,
Chang HM, Bao L, Sun HC, Macarulla T, Xie F, et al: Zanidatamab for
HER2-amplified, unresectable, locally advanced or metastatic
biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm,
phase 2b study. Lancet Oncol. 24:772–782. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tsilimigras DI, Stecko H,
Ntanasis-Stathopoulos I and Pawlik TM: Racial and sex differences
in genomic profiling of intrahepatic cholangiocarcinoma. Ann Surg
Oncol. 31:9071–9078. 2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Jung KW, Won YJ, Kong HJ and Lee ES:
Community of Population-Based Regional Cancer Registries. Cancer
statistics in Korea: Incidence, mortality, survival, and prevalence
in 2015. Cancer Res Treat. 50:303–316. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ,
Kong HJ, Im JS and Seo HG: Community of Population-Based Regional
Cancer Registries. Cancer statistics in Korea: Incidence,
mortality, survival, and prevalence in 2019. Cancer Res Treat.
54:330–344. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ,
Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, et al: Liposomal
irinotecan plus fluorouracil and leucovorin versus fluorouracil and
leucovorin for metastatic biliary tract cancer after progression on
gemcitabine plus cisplatin (NIFTY): A multicentre, open-label,
randomised, phase 2b study. Lancet Oncol. 22:1560–1572.
2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tawarungruang C, Khuntikeo N, Chamadol N,
Laopaiboon V, Thuanman J, Thinkhamrop K, Kelly M and Thinkhamrop B:
Survival after surgery among patients with cholangiocarcinoma in
Northeast Thailand according to anatomical and morphological
classification. BMC Cancer. 21(497)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hang H, Jeong S, Sha M, Kong D, Xi Z, Tong
Y and Xia Q: Cholangiocarcinoma: anatomical location-dependent
clinical, prognostic, and genetic disparities. Ann Transl Med.
7(744)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ren HB, Yu T, Liu C and Li YQ: Diabetes
mellitus and increased risk of biliary tract cancer: Systematic
review and meta-analysis. Cancer Causes Control. 22:837–847.
2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Schlesinger S, Aleksandrova K, Pischon T,
Jenab M, Fedirko V, Trepo E, Overvad K, Roswall N, Tjønneland A,
Boutron-Ruault MC, et al: Diabetes mellitus, insulin treatment,
diabetes duration, and risk of biliary tract cancer and
hepatocellular carcinoma in a European cohort. Ann Oncol.
24:2449–2455. 2013.PubMed/NCBI View Article : Google Scholar
|
